Most people still think obesity is a willpower problem.
Retatrutide phase 3 just made that argument very hard to defend
Ozempic hits one receptor.
Tirzepatide hits two.
Retatrutide hits three.
The third receptor, glucagon, does something the others don't. It turns up fat burning while the others just turn down appetite. The body starts oxidizing stored fat for fuel. Metabolism changes at a structural level.
The Phase 3 numbers:
85 pounds lost on average at two years. No plateau.
65% of patients dropped below the obesity BMI threshold entirely
Liver fat down 82%. Sleep apnea down 60%. Type 2 diabetes reversed in 46%.
Bariatric surgery produces 25 to 30% weight loss. Reta produces 30% from a weekly injection.
What strikes me most is what this signals beyond obesity
We are entering an era where specific biological pathways can be targeted with precision tools that produce predictable outcomes.
Reta is the clearest proof of concept yet. Metabolism is not fixed.
It is programmable.
The same logic applies to aging, cognitive function, fertility, and inflammation. The tools are getting sharper across every category simultaneously.
Where do you think this goes when reta hits the market and the next generation of triple and quad agonists follow?